FEMY · Femasys Inc · Insider Trading

The purchase price paid by the reporting person for the Shares was $3.20 per share pursuant to the Securities Purchase Agreement, dated as of August 7, 2026, by and among Femasys Inc. and the purchasers party thereto.

Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $50,000.

The Common Warrant (Milestone) is exercisable only from and after the Milestone Date, being the first date on or after August 10, 2027 on which both (i) the Company has achieved U.S. revenue of $1,500,000 for any fiscal quarter, as reported in a Form 10-Q or Form 10-K, and (ii) the volume-weighted average price of the Common Stock has satisfied certain price conditions specified in the warrant. The warrant expires on the earlier of (i) three years after the effective date of a registration statement registering the resale of the Warrant Shares and (ii) 45 days after the Company delivers notice that the Milestone Date has occurred. As of the date of this report, neither the Milestone Date nor the expiration date is determinable.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $10,000.

The Common Warrant (Milestone) is exercisable only from and after the Milestone Date, being the first date on or after August 10, 2027 on which both (i) the Company has achieved U.S. revenue of $1,500,000 for any fiscal quarter, as reported in a Form 10-Q or Form 10-K, and (ii) the volume-weighted average price of the Common Stock has satisfied certain price conditions specified in the warrant. The warrant expires on the earlier of (i) three years after the effective date of a registration statement registering the resale of the Warrant Shares and (ii) 45 days after the Company delivers notice that the Milestone Date has occurred. As of the date of this report, neither the Milestone Date nor the expiration date is determinable.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $14,000.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

The purchase price paid by the reporting person for the Shares was $3.20 per share pursuant to the Securities Purchase Agreement, dated as of August 7, 2026, by and among Femasys Inc. and the purchasers party thereto.

Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $10,000.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $50,000.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

The purchase price paid by the reporting person for the Shares was $3.20 per share pursuant to the Securities Purchase Agreement, dated as of August 7, 2026, by and among Femasys Inc. and the purchasers party thereto.

The purchase price paid by the reporting person for the Shares was $3.20 per share pursuant to the Securities Purchase Agreement, dated as of August 7, 2026, by and among Femasys Inc. and the purchasers party thereto.

Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $10,000.

The Common Warrant (Milestone) is exercisable only from and after the Milestone Date, being the first date on or after August 10, 2027 on which both (i) the Company has achieved U.S. revenue of $1,500,000 for any fiscal quarter, as reported in a Form 10-Q or Form 10-K, and (ii) the volume-weighted average price of the Common Stock has satisfied certain price conditions specified in the warrant. The warrant expires on the earlier of (i) three years after the effective date of a registration statement registering the resale of the Warrant Shares and (ii) 45 days after the Company delivers notice that the Milestone Date has occurred. As of the date of this report, neither the Milestone Date nor the expiration date is determinable.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $50,000.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

The purchase price paid by the reporting person for the Shares was $3.20 per share pursuant to the Securities Purchase Agreement, dated as of August 7, 2026, by and among Femasys Inc. and the purchasers party thereto.

Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $14,000.

The Common Warrant (Milestone) is exercisable only from and after the Milestone Date, being the first date on or after August 10, 2027 on which both (i) the Company has achieved U.S. revenue of $1,500,000 for any fiscal quarter, as reported in a Form 10-Q or Form 10-K, and (ii) the volume-weighted average price of the Common Stock has satisfied certain price conditions specified in the warrant. The warrant expires on the earlier of (i) three years after the effective date of a registration statement registering the resale of the Warrant Shares and (ii) 45 days after the Company delivers notice that the Milestone Date has occurred. As of the date of this report, neither the Milestone Date nor the expiration date is determinable.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $10,000.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Holder may, at its option, exercise the Common Warrant, subject to the terms and conditions thereof, at an exercise price of $2.95 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Common Warrant and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $50,000.

The Common Warrant (Milestone) is exercisable only from and after the Milestone Date, being the first date on or after August 10, 2027 on which both (i) the Company has achieved U.S. revenue of $1,500,000 for any fiscal quarter, as reported in a Form 10-Q or Form 10-K, and (ii) the volume-weighted average price of the Common Stock has satisfied certain price conditions specified in the warrant. The warrant expires on the earlier of (i) three years after the effective date of a registration statement registering the resale of the Warrant Shares and (ii) 45 days after the Company delivers notice that the Milestone Date has occurred. As of the date of this report, neither the Milestone Date nor the expiration date is determinable.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

The shares underlying the stock option vest equally in installments over 4 years beginning on July 6, 2027, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date.

The shares underlying the stock option vest one year from the date of grant, assuming continued service.

The shares underlying the stock option vest one year from the date of grant, assuming continued service.

The shares underlying the stock option vest one year from the date of grant, assuming continued service.

The shares underlying the stock option vest one year from the date of grant, assuming continued service.

The shares underlying the stock option vest equally in installments over 4 years beginning on March 30, 2027, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date.

Holder may, at its option, exercise the Series D-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.58 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series D-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were issued to the reporting person in a private placement as consideration in connection with that certain Omnibus Amendment and Consent Agreement, dated as of March 19, 2026 by and among the Company, the reporting person and the other parties thereto.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Holder may, at its option, exercise the Series D-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.58 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series D-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were issued to the reporting person in a private placement as consideration in connection with that certain Omnibus Amendment and Consent Agreement, dated as of March 19, 2026 by and among the Company, the reporting person and the other parties thereto.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Holder may, at its option, exercise the Series D-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.58 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series D-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were issued to the reporting person in a private placement as consideration in connection with that certain Omnibus Amendment and Consent Agreement, dated as of March 19, 2026 by and among the Company, the reporting person and the other parties thereto.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Holder may, at its option, exercise the Series D-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.58 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series D-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were issued to the reporting person in a private placement as consideration in connection with that certain Omnibus Amendment and Consent Agreement, dated as of March 19, 2026 by and among the Company, the reporting person and the other parties thereto.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

The shares underlying the stock option will vest in annual one-third (1/3) increments over a three (3) year period beginning on March 18, 2027, assuming continued service.

Each restricted stock unit represents a contingent right to receive one share of FEMY common stock.

The restricted stock units fully vest on February 19, 2027, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date.

Each restricted stock unit represents a contingent right to receive one share of FEMY common stock.

The restricted stock units fully vest on February 19, 2027, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date.

Each restricted stock unit represents a contingent right to receive one share of FEMY common stock.

The restricted stock units vest in 4 equal annual installments beginning February 19, 2027, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date.

Each restricted stock unit represents a contingent right to receive one share of FEMY common stock.

The restricted stock units vest in 4 equal annual installments beginning February 19, 2027, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date.

Each restricted stock unit represents a contingent right to receive one share of FEMY common stock.

The restricted stock units vest in 4 equal annual installments beginning February 2, 2027, provided that the reporting person is employed by the Issuer or a subsidiary of the Issuer on the vesting date.

Holder may, at its option, exercise the Series C-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $1.10 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series C-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $25,000.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Holder may, at its option, prior to maturity, convert all or any portion of the outstanding amount of Senior Secured Convertible Notes due 2035 (the "Convertible Notes"), including accrued paid in-kind interest thereon, subject to certain limitations, into shares of Common Stock, at an initial conversion price of $0.73 per share of Common Stock. The conversion rate is subject to adjustment in accordance with the terms of the Convertible Notes and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $25,000.

Represents the maximum number of shares of Common Stock issuable upon the voluntary conversion of the original stated amount of the Convertible Notes. The number of shares issuable upon conversion of the Convertible Notes is subject to increase in connection with the accrual of interest, which is payable in kind. The Holder's ability to convert the Convertible Notes to shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Holder may, at its option, exercise the Series A-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.81 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series A-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $50,000.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Holder may, at its option, exercise the Series C-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $1.10 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series C-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $25,000.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Holder may, at its option, exercise the Series B-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.92 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series B-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $25,000.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Holder may, at its option, exercise the Series A-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.81 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series A-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $25,000.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Holder may, at its option, exercise the Series A-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.81 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series A-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $25,000.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Holder may, at its option, prior to maturity, convert all or any portion of the outstanding amount of Senior Secured Convertible Notes due 2035 (the "Convertible Notes"), including accrued paid in-kind interest thereon, subject to certain limitations, into shares of Common Stock, at an initial conversion price of $0.73 per share of Common Stock. The conversion rate is subject to adjustment in accordance with the terms of the Convertible Notes and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $50,000.

Represents the maximum number of shares of Common Stock issuable upon the voluntary conversion of the original stated amount of the Convertible Notes. The number of shares issuable upon conversion of the Convertible Notes is subject to increase in connection with the accrual of interest, which is payable in kind. The Holder's ability to convert the Convertible Notes to shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Holder may, at its option, exercise the Series B-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.92 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series B-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $25,000.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Holder may, at its option, exercise the Series B-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $0.92 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series B-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $50,000.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Holder may, at its option, prior to maturity, convert all or any portion of the outstanding amount of Senior Secured Convertible Notes due 2035 (the "Convertible Notes"), including accrued paid in-kind interest thereon, subject to certain limitations, into shares of Common Stock, at an initial conversion price of $0.73 per share of Common Stock. The conversion rate is subject to adjustment in accordance with the terms of the Convertible Notes and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $25,000.

Represents the maximum number of shares of Common Stock issuable upon the voluntary conversion of the original stated amount of the Convertible Notes. The number of shares issuable upon conversion of the Convertible Notes is subject to increase in connection with the accrual of interest, which is payable in kind. The Holder's ability to convert the Convertible Notes to shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

Holder may, at its option, exercise the Series C-1 Warrants, subject to the terms and conditions thereof, at an initial exercise price of $1.10 per share of Common Stock. The exercise price is subject to adjustment in accordance with the terms of the Series C-1 Warrants and will be subject to standard adjustments in the event of any stock split, stock dividend, stock combination, recapitalization or other similar transactions.

The reported securities were purchased by the reporting person for an aggregate amount of $50,000.

The Holder's ability to exercise the subject Warrant for shares of Common Stock is subject to certain limitations, in accordance with rules of the Nasdaq Capital Market.

The reported securities are included within 38,828 Units purchased by the reporting person for $0.5151 per Unit in an underwritten public offering pursuant to the Registration Statement on Form S-1 (File No. 333-289722). Each Unit consists of one share of common stock and one warrant to purchase one share of common stock.

The reported securities are included within 48,535 Units purchased by the reporting person for $0.5151 per Unit in an underwritten public offering pursuant to the Registration Statement on Form S-1 (File No. 333-289722). Each Unit consists of one share of common stock and one warrant to purchase one share of common stock.

The reported securities are included within 38,828 Units purchased by the reporting person for $0.5151 per Unit in an underwritten public offering pursuant to the Registration Statement on Form S-1 (File No. 333-289722). Each Unit consists of one share of common stock and one warrant to purchase one share of common stock.

The reported securities are included within 48,535 Units purchased by the reporting person for $0.5151 per Unit in an underwritten public offering pursuant to the Registration Statement on Form S-1 (File No. 333-289722). Each Unit consists of one share of common stock and one warrant to purchase one share of common stock.

The shares underlying the stock option vest one year from the date of grant, assuming continued service.

The shares underlying the stock option vest one year from the date of grant, assuming continued service.

The shares underlying the stock option vest one year from the date of grant, assuming continued service.